kanamycin a has been researched along with nicotinamide-beta-riboside in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Dong, H; Fang, J; Mao, S; Shi, H; Su, K; Wu, H; Xing, Y; Yu, D; Zhang, J | 1 |
1 other study(ies) available for kanamycin a and nicotinamide-beta-riboside
| Article | Year |
|---|---|
A reduced form of nicotinamide riboside protects the cochlea against aminoglycoside-induced ototoxicity by SIRT1 activation.
Topics: 14-3-3 Proteins; Aminoglycosides; Animals; Anti-Bacterial Agents; Cochlea; Hearing Loss; Kanamycin; Mice; NAD; Niacinamide; Ototoxicity; Pyridinium Compounds; Reactive Oxygen Species; Resveratrol; Sirtuin 1 | 2022 |